Abstract: Systems and methods for wallet steering are disclosed. A wallet steering method in accordance with the present disclosure may comprise receiving a consumer identifier, such as a phone number, during a transaction. In response to receiving the consumer identifier, a consumer member profile is automatically created for the consumer identifier and data elements associated with the transaction and/or consumer are be stored in the consumer member profile. The consumer member profile may be built over time based on transactions associated with the consumer identifier. Customized offers which precisely and profitably steer consumer purchases from one business to another, one product/service to another and/or one payment tender to another may then be generated based on the consumer profile.

Abstract: Systems and methods for wallet steering are disclosed. A wallet steering method in accordance with the present disclosure may comprise receiving a consumer identifier, such as a phone number, during a transaction. In response to receiving the consumer identifier, a consumer member profile is automatically created for the consumer identifier and data elements associated with the transaction and/or consumer are be stored in the consumer member profile. The consumer member profile may be built over time based on transactions associated with the consumer identifier. Customized offers which precisely and profitably steer consumer purchases from one business to another, one product/service to another and/or one payment tender to another may then be generated based on the consumer profile.

Abstract: The present invention relates to methods of treating or preventing cholesterol related disorders, such as hypercholesterolemia, hyperlipidemia or dyslipidemia, using antibodies against proprotein convertase subtilisin/kexin type 9 (PCSK9). Formulations and methods of producing said formulations are also described.

Abstract: Provided herein are combinations of therapies that provide for the treatment, including regression, of atherosclerosis and/or improvement of cardiovascular outcomes. Generally described, this includes a first, non-PCSK9 LDL-C lowering agent (such as a statin or other non-PCSK9 LDL-C lowering therapy), combined with a second, PCSK9 inhibitor therapy (such as a PCSK9 antibody or anti-RNA). The application of both therapies, at adequately elevated levels so as to reduce the LDL-C level of the subject to very low levels, for an adequate period of time, has been determined to provide an added benefit of further protection from atherosclerosis and improve a subject's cardiovascular outcomes.

Abstract: Disclosed herein are combination therapies for the treatment of heart failure using a cardiac myosin activator, such as omecamtiv mecarbil, and a sinus node If current inhibitor, such as ivabradine. Also disclosed herein are compositions comprising a cardiac myosin activator and a sinus node If current inhibitor.

Abstract: Disclosed herein are combination therapies for the treatment of heart failure using a cardiac myosin activator, such as omecamtiv mecarbil, and a sinus node If current inhibitor, such as ivabradine. Also disclosed herein are compositions comprising a cardiac myosin activator and a sinus node If current inhibitor.

Abstract: Disclosed herein are combination therapies for the treatment of heart failure using a cardiac myosin activator, such as omecamtiv mecarbil, and a sinus node If current inhibitor, such as ivabradine. Also disclosed herein are compositions comprising a cardiac myosin activator and a sinus node If current inhibitor.

Abstract: The present invention relates to methods for treating homozygous familial hypercholesterolemia using antibodies against proprotein convertase subtilisin/kexin type 9 (PCSK9).

Abstract: The invention is directed to a method for increasing bone mineral density (BMD) in a postmenopausal woman. The method comprises administering to a postmenopausal woman having a lumbar vertebrae T-score of less than or equal to ?2 an anti-sclerostin antibody in an amount and for a time effective to increase lumbar vertebrae BMD at least about 9% from pretreatment baseline at twelve months following initial anti-sclerostin antibody administration. The invention also is directed to a method for treating osteoporosis. The method comprising administering to a postmenopausal woman with osteoporosis an anti-sclerostin antibody in an amount of about 70 mg to about 210 mg at once a month, optionally for about three to about 18 months. Alternatively, the method comprises administering an anti-sclerostin antibody in an amount of about 140 mg to about 210 mg every three months, optionally about six to about 18 months.

Abstract: The present invention relates to methods of treating or preventing cholesterol related disorders, such as hypercholesterolemia, hyperlipidemia or dyslipidemia, using antibodies against proprotein convertase subtilisin/kexin type 9 (PCSK9). Formulations and methods of producing said formulations are also described.

Abstract: The present invention relates to methods of treating or preventing cholesterol related disorders, such as hypercholesterolemia, hyperlipidemia or dyslipidemia, using antibodies against proprotein convertase subtilisin/kexin type 9 (PCSK9). Formulations and methods of producing said formulations are also described.

Abstract: The present invention is a telecommunications cable comprising a plurality of electrical conductors, each conductor being surrounded by a layer of insulation comprising a coupled propylene polymer. It is preferable that the propylene polymer be an impact modified propylene polymer, more preferably an impact propylene polymer. The primary advantages of the insulation composition are realized under high-speed extrusion conditions for thin-walled insulation application, including the advantages of smooth insulation surface, good dimensional uniformity, and relatively low extrusion head and die pressures.

Abstract: This invention is directed to optical cable components fabricated from an extrudable blend of high crystalline polypropylene and an impact modifying polymer to provide an enhanced balance flexural modulus, Izod notched value, grease resistance, and low shrinkage properties. The polypropylene has a crystallinity of greater than weight percent and a melt flow of from 1 to 20 grams per 10 minutes at 230 degrees C. At 23 degrees C., the composition yields an extrudant having a 1-percent secant modulus of at least 1,600 MPa and a notched Izod of at least 35 J/m. The composition also yields an extruded tube having a shrinkage of less than 2.0 percent after 24 hours at 100 degrees C.

Abstract: The present invention is a cable comprising one or more telecommunication or power transmission media or a core of two or more such media, each medium or core surrounded by at least one jacketing or sheathing layer comprising a polypropylene homopolymer or copolymer and having a relaxation spectrum (RSI) and melt flow (MF) such RSI*MF{circumflex over (?)}a is greater than about 12 when a is about 0.5. Significantly, the jacketing or sheathing layer exhibits advantaged extrusion fabrication charateristics, resulting from the propylene polymer having enhanced rheology properties (as demonstrated by its high relaxation spectrum index (RSI)). Additionally, the propylene-based polymer composition of the present invention exhibits relaxtively high melt strength compared to compounds of conventional propylene polymers or ethylene polymers. In fiber optic cable jacketing applications, the present invention advantageously balances low post extrusion shrinkage with high modulus/deformation resistance.